Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoriasis-Arthritis & Bone Program)
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PSARTROS
- 30 Nov 2017 Status changed from recruiting to completed.
- 08 Nov 2017 Results (n=20) assessing short term efficacy, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 17 Jun 2017 Results (n=20) assessing short term efficacy presented at the 18th Annual Congress of the European League Against Rheumatism.